

Constellation Pharmaceuticals

05:55 21 May 2019

Constellation Pharmaceuticals presents poster on studies involving drug therapy to treat bladder cancer

Constellation Pharmaceuticals Inc (NASDAQ:CNST) fell into the red Monday on the same day the company presented a poster on studies involving the company's drug therapy to treat bladder cancer.

The Cambridge, Massachusetts-based company's stock recently traded at \$8.99 a share, down 15.4% on higher-than-average volume.

Patricia Keller, senior scientist at Constellation, made the poster presentation titled "targeting epigenetic dysregulation in bladder cancer through inhibition of EZH2" at the Bladder Cancer: Transforming the Field meeting of the American Association for Cancer Research in Denver.

The poster discusses results of Constellation's work with its second-generation EZH2 inhibitor CPI-0209 in bladder cancer models, exploring whether ARID1A mutation status affected responsiveness to CPI-0209 treatment, according to a statement.

ARID1A, a protein that is a key component of the SWI/SNF chromatin remodeling complex, is mutated in about 25% of muscle-invasive bladder cancers, the company said.

Constellation used CPI-0209 in long-term phenotypic growth assays in a panel of 21 bladder cancer cell lines, demonstrating preferential treatment sensitivity that correlated with increased cell death in cell lines harboring ARID1A mutations. Transcriptional profiling after CPI-0209 treatment showed widespread activation of EZH2 target gene expression, the company said.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: US\$9.84

Market Cap: US\$256.27M

1 Year Share Price Graph



Share Information

Code: CNST

Listing: NASDAQ

52 week High Low
\$14.04 \$4.04

Sector: Health Care, Equipment & Services

Website:

Company Synopsis:

Constellation Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that

neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek personal advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.